Caris Life Sciences, an AI-driven precision oncology company, is targeting a $5.35 billion valuation in its U.S. initial ...

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

Moderna declined to comment. As a condition for approving the new shot, the FDA required a future placebo-controlled study in adults ages 50 to 64 without high-risk conditions, according to agency ...

Moderna Inc. has agreed to do a placebo-controlled trial of its new Covid vaccine that was recently approved by US regulators, Health and Human Services Secretary Robert F. Kennedy Jr. said Tuesday.

The Trump administration has canceled $766 million awarded to Moderna to develop a vaccine against potential pandemic influenza viruses, including the H5N1 bird flu.

Moderna could face suspension from Britain’s pharmaceutical trade body following a string of breaches of the regulatory code. The Covid vaccine maker is due to be audited by the Prescription ...

Last year, Moderna began a Phase 1/2 clinical trial to test the safety and immune response of several vaccines in this program, including vaccines designed to address the H5 and H7 avian influenza ...

SOPA Images / Contributor / Getty Images Moderna Inc. said it has a “next-generation COVID-19 vaccine," which it wants to use as part of a combination COVID-flu treatment. The biotech firm said ...

Moderna and Merck’s new mRNA vaccine reduces the chance of relapse or death of skin cancer by half when paired with Merck’s immunotherapy drug Keytruda, new data shows, marking a step forward ...

Moderna revealed Wednesday that its flu vaccine using mRNA technology has offered promising results as the flu season begins to ramp up. Moderna announced that its seasonal flu vaccine ...

Moderna is set to launch a phase 1/2 trial of the shot this summer, Hamilton Bennett, senior director of vaccine access and partnerships at Moderna, said in an interview at the the BIO ...

Moderna is eyeing testing two vaccine candidates, one for mpox and another for bird flu, in humans later this year, Bloomberg reported March 6. The drugmaker’s president, Stephen Hoge, MD, said ...